Apotex Receives Health Canada Approval for LOQTORZI® - The First and Only Immuno-Therapy for Recurrent Unresectable or Metastatic Nasopharyngeal Cancer
Oct 23, 2025Toronto, ON - October 23, 2025 - Apotex Inc. ("Apotex" or the "Company"), the largest Canadian-based pharmaceutical company, today announced that Health Canada has granted a Notice of Compliance (NOC) for LOQTORZI® (toripalimab) for the treatment of nasopharyngeal carcinoma (NPC), an ultra-rare and aggressive cancer.
This approval marks a significant milestone. LOQTORZI is the first and only Health Canada-approved immuno-therapy for patients with recurrent unresectable or metastatic nasopharyngeal cancer (R/M NPC), offering an effective new immuno-therapy option to patients facing this challenging malignancy.
- In combination with cisplatin and gemcitabine for adults with metastatic or recurrent locally advanced NPC.
- As a monotherapy for adults with recurrent unresectable or metastatic NPC who have progressed following platinum-based chemotherapy.1
This approval introduces Apotex's first novel biologic therapy, a targeted immuno-therapy, underscoring the company's commitment to expanding access to innovative oncology treatments in Canada. It represents a strategic evolution of Apotex's portfolio, which includes providing options for patients with rare and hard-to-treat cancers. Apotex secured the Canadian rights to LOQTORZI through an agreement with Coherus BioSciences.
"LOQTORZI exemplifies our commitment to Canadian patients and the healthcare system," said Allan Oberman, President & CEO, Apotex. "As the first and only Health Canada-approved immuno-therapy for both the first and later-line treatment of this unique cancer, it delivers a transformative therapy where none previously existed, addressing a critical unmet need."
"The availability of LOQTORZI in Canada is a meaningful step forward for patients diagnosed with nasopharyngeal carcinoma," said Dr. Nathaniel Bouganim, Medical Oncologist and Division Director of Medical Oncology, McGill University Health Centre. "Having this therapy accessible through a Canadian-based pharmaceutical company like Apotex helps promote equitable care for those facing this rare disease."
As a Force for Health, Apotex continues to build on its strategic vision, expanding its presence in pharmaceutical and consumer health products while maintaining its core focus on improving everyday access to critical medicines for patients.
Please consult the product monograph available at: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106511 for complete prescribing information, warnings and precautions, adverse reactions, and contraindications.
-30-
Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.
Learn more at www.apotex.com.
Media Contact:
Apotex [email protected]
[1] toripalimab | CDA-AMC
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Sep 18, 2026
Apotex Health Corp. announces closing of upsized bought deal secondary offering
Toronto, Ontario, September 18, 2026 – Apotex Health Corp. ("Apotex" or the "Company") announced today the closing of the previously announced upsized secondary offering (the "Offering") of common shares of the Company (the "Common Shares") by an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders").
-
Sep 15, 2026
Apotex Health Corp. announces upsize of bought deal secondary offering to $850 million
Toronto, Ontario, September 15, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that, as a result of strong demand, Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an amended agreement with the syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to increase the size of the previously announced bought deal secondary offering of common shares of the Company (the "Common Shares"). Under the amended agreement, the Underwriters have agreed to purchase 25,000,000 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $850,000,000 (the "Upsized Offering").
-
Sep 15, 2026
Apotex Health Corp. announces $750 million bought deal secondary offering
Toronto, Ontario, September 14, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an agreement with a syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to complete a secondary offering on a bought deal basis (the "Offering") of common shares of the Company (the "Common Shares"). Under the agreement, the Underwriters have agreed to purchase 22,058,825 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $750,000,050.